The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Ranexa 500 mg prolonged-release tablets

Menarini International Operations Luxembourg S.A.EU/1/08/462/3,4,9,10

Main Information

Trade NameRanexa 500 mg prolonged-release tablets
Active SubstancesRanolazine
Dosage FormProlonged-release tablet
Licence HolderMenarini International Operations Luxembourg S.A.
Licence NumberEU/1/08/462/3,4,9,10

Group Information

ATC CodeC01EB Other cardiac preparations


License statusAuthorised
Licence Issued
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back